Milestone cuts expenses to extend cash runway through AFib-RVR Phase 3 readout
Milestone Pharmaceuticals Q3 revenue surged 73% to $1.0 million as net prescriptions crossed 3,400. To extend cash runway into late 2028 for an upcoming Phase 3 trial, the company is reducing operating expenses by 30% and extending debt payment terms.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed